Perseus Proteomics Inc. Logo

Perseus Proteomics Inc.

Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.

4882 | T

Overview

Corporate Details

ISIN(s):
JP3836800007
LEI:
Country:
Japan
Address:
目黒区駒場四丁目7番6号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perseus Proteomics Inc. is a drug discovery biotechnology company founded in 2001 as a venture from the University of Tokyo. The company focuses on creating novel antibody-based therapeutics to treat cancer and other diseases, utilizing its proprietary and unique antibody technologies. Its business operations are structured around three core segments: Drug Discovery, which develops its pipeline of potential antibody drugs; Antibody Research Support Services for partner institutions; and the direct sale of antibody products and diagnostic reagents, such as ELISA kits. The company's mission is to contribute to global healthcare by developing innovative treatments for people suffering from diseases worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:32
Registration Form
確認書
Japanese 8.2 KB
2025-11-14 07:32
Interim Report
半期報告書-第26期(2025/04/01-2026/03/31)
Japanese 160.8 KB
2025-06-27 09:28
Post-Annual General Meeting Information
臨時報告書
Japanese 25.9 KB
2025-06-27 08:34
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 08:33
Registration Form
訂正有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2025-06-27 08:33
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 08:32
Annual Report
訂正有価証券報告書-第23期(2022/04/01-2023/03/31)
Japanese 1.5 MB
2025-06-27 08:32
Governance Information
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.4 KB
2025-06-27 08:31
Registration Form
確認書
Japanese 8.1 KB
2025-06-27 08:31
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 2.6 MB
2025-05-21 08:31
Regulatory News Service
臨時報告書
Japanese 20.2 KB
2024-11-14 07:34
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 07:34
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 163.4 KB
2024-06-20 07:40
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2024-06-20 07:34
Governance Information
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB

Automate Your Workflow. Get a real-time feed of all Perseus Proteomics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perseus Proteomics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perseus Proteomics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.